See more : Future Enterprises Limited (FELDVR.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Quantum-Si incorporated (QSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quantum-Si incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- FAR Limited (FAR.AX) Income Statement Analysis – Financial Results
- Harfang Exploration Inc. (HRFEF) Income Statement Analysis – Financial Results
- ASE Technology Holding Co., Ltd. (3711.TW) Income Statement Analysis – Financial Results
- Janover Inc. (JNVR) Income Statement Analysis – Financial Results
- Corby Spirit and Wine Limited (CBYDF) Income Statement Analysis – Financial Results
Quantum-Si incorporated (QSI)
About Quantum-Si incorporated
Quantum-Si incorporated, a life sciences company, develops a single molecule detection platform for sample preparation and sequencing. It offers a proprietary single molecule detection platform for use in semiconductor industry to field proteomics to enable next generation protein sequencing. The company was incorporated in 2013 is based in Guilford, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 594.00K | 2.58M | 1.04M | 894.00K | 0.00 |
| Gross Profit | 488.00K | -2.58M | -1.04M | -894.00K | 0.00 |
| Gross Profit Ratio | 45.10% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 67.03M | 72.06M | 46.58M | 27.56M | 28.10M |
| General & Administrative | 42.81M | 42.29M | 46.38M | 7.98M | 7.88M |
| Selling & Marketing | 400.00K | 7.00K | 3.96M | 1.15M | 634.00K |
| SG&A | 44.63M | 42.30M | 50.33M | 9.14M | 8.52M |
| Other Expenses | 0.00 | -20.15M | -5.00M | -10.00K | 5.00K |
| Operating Expenses | 111.66M | 114.36M | 96.91M | 36.69M | 36.62M |
| Cost & Expenses | 112.25M | 114.36M | 96.91M | 36.69M | 36.62M |
| Interest Income | 0.00 | 0.00 | 2.54M | 88.00K | 823.00K |
| Interest Expense | 0.00 | 0.00 | 5.00K | 9.00K | 0.00 |
| Depreciation & Amortization | 4.16M | 2.58M | 1.04M | 894.00K | 780.00K |
| EBITDA | -91.80M | -129.86M | -95.87M | -35.80M | -35.84M |
| EBITDA Ratio | -8,484.66% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -111.17M | -123.84M | -96.91M | -36.69M | -36.62M |
| Operating Income Ratio | -10,274.58% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 15.21M | -8.60M | 1.92M | 78.00K | 828.00K |
| Income Before Tax | -95.96M | -132.44M | -94.99M | -36.61M | -35.79M |
| Income Before Tax Ratio | -8,868.76% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 8.60M | -6.04M | -1.00K | 5.00K |
| Net Income | -95.96M | -141.04M | -88.95M | -36.61M | -35.80M |
| Net Income Ratio | -8,868.76% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.68 | -1.01 | -1.12 | -6.81 | -0.26 |
| EPS Diluted | -0.68 | -1.01 | -1.12 | -6.81 | -0.26 |
| Weighted Avg Shares Out | 141.30M | 139.26M | 79.58M | 5.38M | 136.40M |
| Weighted Avg Shares Out (Dil) | 141.30M | 139.26M | 79.58M | 5.38M | 136.40M |
Quantum-Si to Participate in B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation, Virtual Conference
GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation, Virtual...
Quantum-Si Reports Fourth Quarter and Fiscal Year 2022 Financial Results
GUILFORD, Conn.--(BUSINESS WIRE)--March 6, 2023--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022. Recent Business Highlights Launched Platinum, the world’s first...
Quantum-Si Reports Fourth Quarter and Fiscal Year 2022 Financial Results
GUILFORD, Conn.--(BUSINESS WIRE)--March 6, 2023--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022.
Quantum-Si to Participate in the 43rd Annual Cowen Health Care Conference
GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in the 43rd Annual Cowen Health Care Conference taking place at the Boston Marriott Copley Place, Boston, MA...
Quantum-Si to Participate in the 43rd Annual Cowen Health Care Conference
GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in the 43rd Annual Cowen Health Care Conference taking place at the Boston Marriott Copley Place, Boston, MA...
Quantum-Si to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will report financial results for the fourth quarter and full year 2022 before market open on Monday, March 6, 2023. Company...
Quantum-Si Begins Commercial Shipments of the PlatinumTM Protein Sequencing System and Provides Business Updates at the 41st Annual J.P. Morgan Healthcare Conference
GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that management will discuss the following business updates at the 41st Annual J.P. Morgan Healthcare Conference. Business Updates Quantum-Si has begun commercial shipments...
Quantum-Si Begins Commercial Shipments of the PlatinumTM Protein Sequencing System and Provides Business Updates at the 41st Annual J.P. Morgan Healthcare Conference
GUILFORD, Conn.--( BUSINESS WIRE )--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that management will discuss the following business updates at the 41st Annual J.P. Morgan Healthcare Conference.
Quantum-Si and Aviva Systems Biology Partner to Co-Develop Sample Preparation Kits for Protein Sequencing
GUILFORD, Conn.--( BUSINESS WIRE )--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it entered into a partnership with Aviva Systems Biology, a leading provider of antibody, protein, and immunoassay reagent products with...
Quantum-Si and Aviva Systems Biology Partner to Co-Develop Sample Preparation Kits for Protein Sequencing
GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it entered into a partnership with Aviva Systems Biology, a leading provider of antibody, protein, and immunoassay reagent products with an extensive...
Source: https://incomestatements.info
Category: Stock Reports